Skip to content

Mobile Mindfulness Training (mMT) for People in Medication Treatment of Opioid Use Disorder (MOUD)

Improving Opioid Use Disorder Treatment Engagement Using Mobile Mindfulness in Childhood Trauma Survivors

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06857968
Enrollment
60
Registered
2025-03-05
Start date
2025-07-29
Completion date
2029-01-01
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Keywords

opioid use disorder, mindfulness, childhood trauma, treatment

Brief summary

The goal of this clinical trial is to learn if mobile mindfulness training can help people in treatment for opioid use disorder. The main questions it aims to answer are: * Will people with opioid use disorder and childhood trauma use mobile mindfulness training? * Will mobile mindfulness training help people with opioid use disorder and childhood trauma have decreased markers of psychological stress? Participants will: Be given access to mobile mindfulness training and encouragement to use it daily for 30 days. Keep a diary of how often mobile mindfulness training is used. Visit the clinic four times to measure stress levels, including written rating scales, blood work, and heart rate tests.

Interventions

BEHAVIORALMobile Mindfulness Training

Participants will be instructed to complete a mobile application-based mindfulness training daily for 30 days.

Sponsors

Amy Meadows
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Clinically diagnosed with Opioid Use Disorder (per DSM5 criteria) * Currently enrolled in treatment for Opioid Use Disorder at a clinic affiliated with UKHealthCare or University of Kentucky * On a stable dose of buprenorphine, buprenorphine/naloxone, or naloxone (i.e., at least 30 days post-induction and on a stable dose for 30 days) * Able to read and understand English * Have a history of childhood trauma as measured by the Adverse Childhood Experiences scale and/or Childhood Trauma Questionnaire.

Exclusion criteria

* Currently taking a beta-blocker, calcium-channel blocker, antiarrhythmic, corticosteroid, or immune modulator medication * Uncontrolled acute or chronic health conditions (e.g., active infections, autoimmune conditions, cancer undergoing active treatment) * Current or expected pregnancy * Current mindfulness practice (i.e., participant reports practicing mindfulness for 10 minutes or more per week) * Primary psychotic illness * Diagnosis of a disorder known to interfere with neurocognitive function (e.g., estimated full scale IQ below 70 or diagnosis of dementia)

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Access75 days after enrollmentProportion of enrolled participants who access the online mobile mindfulness training (mMT) application at least once.
Proportion of Acceptability75 days after enrollmentProportion of enrolled active condition participants who report using the online mobile mindfulness training application at least 25 times in 30 days.

Secondary

MeasureTime frameDescription
Change in Trauma Symptoms180 days after enrollmentSelf-reported changes in trauma symptoms as measured by the Post-Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual-5 between baseline and 180 days after enrollment. Items are summed to provide a total severity score (range 0-80) with higher scores indicating more symptoms of trauma.
Change in Mindfulness180 days after enrollmentSelf-reported changes in mindfulness between as measured by the Five Factor Mindfulness Questionnaire. The Five Factor Mindfulness Questionnaire (FFMQ). It examines 5 key domains of mindfulness: observing, describing, acting with awareness, nonjudging of inner experience, and nonreactivity to inner experience. Scores range from 39 to 195, with higher scores indicating greater tendency to be mindful.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAmy Meadows, M.D.

University of Kentucky

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026